Morgan Stanley Contrafect Corp Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.09 - $0.19 $2,883 - $6,086	32,036 Added 354.62%	41,070 $4,000
Q3 2022 Nov 14, 2022	SELL	$0.18 - $3.51 $1,872 - $36,507	-10,401 Reduced 53.52%	9,034 $1,000
Q2 2022 Oct 27, 2022	SELL	$2.79 - $4.45 $27,992 - $44,646	-10,033 Reduced 34.05%	19,435 $59,000
Q2 2022 Aug 15, 2022	SELL	$2.79 - $4.45 $27,992 - $44,646	-10,033 Reduced 34.05%	19,435 $59,000
Q1 2022 Oct 27, 2022	BUY	$2.26 - $3.84 $22,674 - $38,526	10,033 Added 51.62%	29,468 $107,000
Q1 2022 May 13, 2022	SELL	$2.26 - $3.84 $194 - $330	-86 Reduced 0.29%	29,468 $107,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $1,733 - $2,906	-702 Reduced 2.32%	29,554 $78,000
Q3 2021 Nov 15, 2021	BUY	$3.19 - $4.43 $96,516 - $134,034	30,256 New	30,256 $122,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.